Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Director Sells $251,300.00 in Stock

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Director Andrew Regan sold 1,005,200 shares of the business’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $0.25, for a total value of $251,300.00. Following the sale, the director now owns 11,936,119 shares of the company’s stock, valued at $2,984,029.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Andrew Regan also recently made the following trade(s):

• On Wednesday, July 17th, Andrew Regan sold 1,514,100 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.26, for a total transaction of $393,666.00.
• On Friday, July 12th, Andrew Regan sold 1,389,820 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.25, for a total transaction of $347,455.00.
• On Wednesday, July 10th, Andrew Regan sold 150,000 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.33, for a total transaction of $49,500.00.
• On Monday, July 8th, Andrew Regan sold 35,923 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.51, for a total transaction of $18,320.73.
• On Wednesday, July 3rd, Andrew Regan sold 1,000 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.64, for a total value of $640.00.

Conduit Pharmaceuticals Trading Down 1.1 %

Shares of NASDAQ:CDT traded down $0.00 during mid-day trading on Thursday, reaching $0.13. 1,313,045 shares of the company traded hands, compared to its average volume of 4,557,714. The company’s 50 day moving average price is $0.18 and its 200-day moving average price is $1.80. Conduit Pharmaceuticals Inc. has a 52 week low of $0.11 and a 52 week high of $22.00.

Conduit Pharmaceuticals (NASDAQ:CDT) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.07) earnings per share for the quarter.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank upgraded Conduit Pharmaceuticals to a “strong-buy” rating in a research report on Friday, July 26th.

About Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.